


At this point, fewer than 2,000 daily cases were being reported worldwide. But demand for the test would soon skyrocket...

By late April 2020, Seegene was exporting 3 million tests per week and had distributed more than 10 million Allplex™ 2019-nCoV tests to more than 60 countries.



RAPID RESPONSE

EFFECTIVE SCALE-UP PRODUCTION

ONGOING LEADERSHIP IN MULTI-ASSAY DIAGNOSTICS



Seegene continues to be a **world leader** in multi-assay diagnostic tests.



In September 2020, Seegene developed the **Novaplex SARS-CoV-2 Variants I Assay**, the world's first COVID-19 test capable of detecting multiple variants in a single reaction. The test acquired MFDS approval for export in January 2021.



The **Novaplex™ SARS-CoV-2/FluA/FluB/RSV assay** can screen and differentiate eight targets for COVID-19, influenza and respiratory syncytial virus.



April 21, 2021: Seegene is set to supply Scotland with £16 million (GBP) worth of COVID-19 diagnostic tests. This is triple the volume supplied to Scotland in 2020.



By mid-2021, over 60 million Seegene's COVID-19 assays had been exported globally.

ABOUT SEEGENE

Seegene is a global in vitro diagnostics (IVD) biotech firm founded in 2000 in South Korea. Seegene's headquarters is located in Seoul, South Korea. Seegene has subsidiaries in the USA, Canada, Germany, Italy, Brazil, Mexico and Dubai.

Visit [SeegeneTech.com](https://www.seegene.com) for updates on testing, new products, distribution and news.

Follow Seegene Technologies on social media.   